Logo image of EXAS

EXACT SCIENCES CORP (EXAS) Stock Fundamental Analysis

NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD

43.17  +1.59 (+3.82%)

Fundamental Rating

3

EXAS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. EXAS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, EXAS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year EXAS has reported negative net income.
EXAS had a positive operating cash flow in the past year.
In the past 5 years EXAS always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: EXAS reported negative operating cash flow in multiple years.
EXAS Yearly Net Income VS EBIT VS OCF VS FCFEXAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M -800M -1B

1.2 Ratios

EXAS's Return On Assets of -17.36% is amongst the best of the industry. EXAS outperforms 80.63% of its industry peers.
The Return On Equity of EXAS (-42.83%) is better than 68.84% of its industry peers.
Industry RankSector Rank
ROA -17.36%
ROE -42.83%
ROIC N/A
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
EXAS Yearly ROA, ROE, ROICEXAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

EXAS has a better Gross Margin (69.55%) than 81.34% of its industry peers.
In the last couple of years the Gross Margin of EXAS has declined.
EXAS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
EXAS Yearly Profit, Operating, Gross MarginsEXAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EXAS has more shares outstanding
Compared to 5 years ago, EXAS has more shares outstanding
The debt/assets ratio for EXAS is higher compared to a year ago.
EXAS Yearly Shares OutstandingEXAS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
EXAS Yearly Total Debt VS Total AssetsEXAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

EXAS has an Altman-Z score of 0.79. This is a bad value and indicates that EXAS is not financially healthy and even has some risk of bankruptcy.
EXAS has a better Altman-Z score (0.79) than 68.13% of its industry peers.
The Debt to FCF ratio of EXAS is 87.70, which is on the high side as it means it would take EXAS, 87.70 years of fcf income to pay off all of its debts.
EXAS has a better Debt to FCF ratio (87.70) than 92.43% of its industry peers.
A Debt/Equity ratio of 0.97 indicates that EXAS is somewhat dependend on debt financing.
EXAS has a worse Debt to Equity ratio (0.97) than 77.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 87.7
Altman-Z 0.79
ROIC/WACCN/A
WACC9.06%
EXAS Yearly LT Debt VS Equity VS FCFEXAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

EXAS has a Current Ratio of 2.15. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
EXAS's Current ratio of 2.15 is on the low side compared to the rest of the industry. EXAS is outperformed by 73.77% of its industry peers.
A Quick Ratio of 1.92 indicates that EXAS should not have too much problems paying its short term obligations.
EXAS has a worse Quick ratio (1.92) than 74.65% of its industry peers.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 1.92
EXAS Yearly Current Assets VS Current LiabilitesEXAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for EXAS have decreased strongly by -388.60% in the last year.
EXAS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.36%.
Measured over the past years, EXAS shows a very strong growth in Revenue. The Revenue has been growing by 25.78% on average per year.
EPS 1Y (TTM)-388.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1629.63%
Revenue 1Y (TTM)10.36%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%10.29%

3.2 Future

EXAS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.14% yearly.
EXAS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.49% yearly.
EPS Next Y91.39%
EPS Next 2Y44.6%
EPS Next 3Y30.7%
EPS Next 5Y20.14%
Revenue Next Year11.24%
Revenue Next 2Y12.13%
Revenue Next 3Y11.91%
Revenue Next 5Y10.49%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EXAS Yearly Revenue VS EstimatesEXAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
EXAS Yearly EPS VS EstimatesEXAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

EXAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EXAS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EXAS Price Earnings VS Forward Price EarningsEXAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

91.73% of the companies in the same industry are more expensive than EXAS, based on the Enterprise Value to EBITDA ratio.
92.78% of the companies in the same industry are more expensive than EXAS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 271.41
EV/EBITDA 248.2
EXAS Per share dataEXAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as EXAS's earnings are expected to grow with 30.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.6%
EPS Next 3Y30.7%

More info and screens

0

5. Dividend

5.1 Amount

EXAS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXACT SCIENCES CORP

NASDAQ:EXAS (4/21/2025, 3:49:04 PM)

43.17

+1.59 (+3.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19 2025-02-19/amc
Earnings (Next)05-01 2025-05-01/amc
Inst Owners100.85%
Inst Owner Change0.09%
Ins Owners0.99%
Ins Owner Change4.46%
Market Cap8.02B
Analysts84.85
Price Target71.33 (65.23%)
Short Float %5.83%
Short Ratio4.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-695.49%
Min EPS beat(2)-1391.93%
Max EPS beat(2)0.95%
EPS beat(4)2
Avg EPS beat(4)-336.22%
Min EPS beat(4)-1391.93%
Max EPS beat(4)72.6%
EPS beat(8)6
Avg EPS beat(8)-142.98%
EPS beat(12)10
Avg EPS beat(12)-89.43%
EPS beat(16)11
Avg EPS beat(16)-65.9%
Revenue beat(2)0
Avg Revenue beat(2)-1.73%
Min Revenue beat(2)-3.19%
Max Revenue beat(2)-0.27%
Revenue beat(4)0
Avg Revenue beat(4)-1.12%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)-0.27%
Revenue beat(8)2
Avg Revenue beat(8)0.62%
Revenue beat(12)6
Avg Revenue beat(12)1.31%
Revenue beat(16)10
Avg Revenue beat(16)1.62%
PT rev (1m)-1.53%
PT rev (3m)-4.46%
EPS NQ rev (1m)5.03%
EPS NQ rev (3m)-7.08%
EPS NY rev (1m)1.8%
EPS NY rev (3m)-6.31%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)-1.63%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.91
P/FCF 271.41
P/OCF 38.09
P/B 3.34
P/tB N/A
EV/EBITDA 248.2
EPS(TTM)-5.57
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)0.16
FCFY0.37%
OCF(TTM)1.13
OCFY2.63%
SpS14.85
BVpS12.93
TBVpS-5.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.36%
ROE -42.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.55%
FCFM 1.07%
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
F-Score3
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 87.7
Debt/EBITDA 65.54
Cap/Depr 84.24%
Cap/Sales 6.56%
Interest Coverage N/A
Cash Conversion 591.13%
Profit Quality N/A
Current Ratio 2.15
Quick Ratio 1.92
Altman-Z 0.79
F-Score3
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)84.38%
Cap/Depr(5y)130.41%
Cap/Sales(3y)7.28%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-388.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1629.63%
EPS Next Y91.39%
EPS Next 2Y44.6%
EPS Next 3Y30.7%
EPS Next 5Y20.14%
Revenue 1Y (TTM)10.36%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%10.29%
Revenue Next Year11.24%
Revenue Next 2Y12.13%
Revenue Next 3Y11.91%
Revenue Next 5Y10.49%
EBIT growth 1Y16.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year307.3%
EBIT Next 3Y79.87%
EBIT Next 5Y51.21%
FCF growth 1Y-5.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.86%
OCF growth 3YN/A
OCF growth 5YN/A